Revance Therapeutics (NASDAQ:RVNC) Sees Large Volume Increase

Share on StockTwits

Revance Therapeutics Inc (NASDAQ:RVNC) saw strong trading volume on Monday . 1,539,251 shares traded hands during trading, an increase of 265% from the previous session’s volume of 421,246 shares.The stock last traded at $20.02 and had previously closed at $17.90.

Several equities analysts have issued reports on RVNC shares. ValuEngine raised shares of Revance Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday. Mizuho restated a “buy” rating and set a $34.00 price target on shares of Revance Therapeutics in a research note on Tuesday, November 5th. Goldman Sachs Group began coverage on shares of Revance Therapeutics in a research report on Monday. They set a “buy” rating and a $25.00 price target for the company. William Blair restated an “outperform” rating on shares of Revance Therapeutics in a research note on Tuesday, August 6th. Finally, Zacks Investment Research downgraded shares of Revance Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, October 17th. One analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $27.88.

The company has a quick ratio of 6.46, a current ratio of 6.46 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $761.46 million, a PE ratio of -4.20 and a beta of 1.26. The business has a 50-day moving average price of $16.01 and a 200-day moving average price of $13.00.

Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.96). The firm had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.40 million. Revance Therapeutics had a negative net margin of 3,745.97% and a negative return on equity of 87.59%. On average, equities research analysts anticipate that Revance Therapeutics Inc will post -3.64 earnings per share for the current year.

Several large investors have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Revance Therapeutics by 86.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,727 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 1,262 shares in the last quarter. FNY Investment Advisers LLC acquired a new position in shares of Revance Therapeutics in the 2nd quarter valued at about $37,000. Quadrant Capital Group LLC acquired a new position in Revance Therapeutics in the third quarter valued at approximately $89,000. Bank of Montreal Can raised its stake in shares of Revance Therapeutics by 217.7% during the second quarter. Bank of Montreal Can now owns 10,301 shares of the biopharmaceutical company’s stock valued at $134,000 after purchasing an additional 7,059 shares in the last quarter. Finally, First Republic Investment Management Inc. acquired a new stake in Revance Therapeutics in the 2nd quarter valued at about $143,000. 94.52% of the stock is owned by hedge funds and other institutional investors.

About Revance Therapeutics (NASDAQ:RVNC)

Revance Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine.

Featured Article: Stock Portfolio Tracker

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.